Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
prostaglandin analogue |
| gptkbp:approvalYear |
1996
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
S01EE01
|
| gptkbp:brand |
gptkb:Xalatan
|
| gptkbp:CASNumber |
130209-82-4
|
| gptkbp:chemicalFormula |
C26H40O5
|
| gptkbp:contraindication |
hypersensitivity to latanoprost
|
| gptkbp:developedBy |
gptkb:Pharmacia
|
| gptkbp:drugClass |
antiglaucoma agent
|
| gptkbp:eliminationHalfLife |
17 minutes (plasma)
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
eye drops
|
| https://www.w3.org/2000/01/rdf-schema#label |
latanoprost
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
increases uveoscleral outflow
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
ophthalmic
|
| gptkbp:sideEffect |
eye irritation
eye redness eyelash growth iris pigmentation |
| gptkbp:synonym |
isopropyl unoprostone
latanoprostum |
| gptkbp:usedFor |
glaucoma
ocular hypertension |
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:Xalatan
|
| gptkbp:bfsLayer |
7
|